Jake S. O’Donnell

4.9k citations

17 papers · 3.1k indexed · 3 hit papers · h-index 12

Impact in

Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Immunology top 2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer

Papers in

Immunology 13
- Immunotherapy and Immune Responses 10
- T-cell and Retrovirus Studies 3
Oncology 11
- Cancer Immunotherapy and Biomarkers 11
- CAR-T cell therapy research 6
- Cancer Cells and Metastasis 2

Co-authors: Michele W.L. Teng Mark J. Smyth Georgina V. Long Richard A. Scolyer Daniela Massi Mario Mandalà Stacey Allen Heidi Harjunpää
Journals: OncoImmunology (3 papers)Seminars in Cancer Biology (2 papers)Frontiers in Microbiology (1 paper)Nature Reviews Clinical Oncology (1 paper)Clinical Cancer Research (1 paper)
Partner nations: Australia Italy Netherlands

In The Last Decade

Jake S. O’Donnell

17 papers receiving 3.1k citations

Hit Papers

align trajectories log scale

Cancer immunoediting and resistance to T cell-based immunotherapy 2018 · 1.3k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 Nature Reviews Clinical Oncology
2016 Cancer Treatment Reviews
2016 Cancer Discovery

Peers

Countries citing papers authored by Jake S. O’Donnell

Since Specialization

Citations

This map shows the geographic impact of Jake S. O’Donnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jake S. O’Donnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jake S. O’Donnell more than expected).

Fields of papers citing papers by Jake S. O’Donnell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jake S. O’Donnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jake S. O’Donnell. The network helps show where Jake S. O’Donnell may publish in the future.

Co-authors

The 25 scholars most cited alongside Jake S. O’Donnell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jake S. O’Donnell Line = papers co-authored together Jake S. O’Donnell links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	Human T-lymphotropic virus type 1 and antiretroviral therapy: practical considerations for pre-exposure and post-exposure prophylaxis, transmission prevention, and mitigation of severe disease The Lancet Microbe ·Jake S. O’Donnell, Ewerton Maia Barbosa, Keith J. Chappell	2024	5
2	HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors Virology Journal ·Livia Mancine Coelho De Campos, Ewerton Maia Barbosa, Valentin Contreras, Keith J. Chappell, Jake S. O’Donnell	2024	5
3	Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma The Lancet Haematology ·Jake S. O’Donnell, 李良城, Keith J. Chappell	2023	10
4	Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccine Frontiers in Immunology ·Jake S. O’Donnell, Ariel Isaacs, Rama Jadallah, A Murray, James Barnes, Patrick C. Reading, Paul R. Young, Daniel Watterson, Patrice Dubois, Nicolas Collin, Keith J. Chappell	2022	8
5	Chronic SARS-CoV-2, a Cause of Post-acute COVID-19 Sequelae (Long-COVID)? Frontiers in Microbiology ·Jake S. O’Donnell, Keith J. Chappell	2021	17
6	Tumor intrinsic and extrinsic immune functions of CD155 Seminars in Cancer Biology ·Jake S. O’Donnell, Jason Madore, Xian-Yang Li, Mark J. Smyth	2019	102
7	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment Clinical Cancer Research ·Jake S. O’Donnell, Esmée P. Hoefsmit, Mark J. Smyth, Christian U. Blank, Michele W.L. Teng	2019	136
8	Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome OncoImmunology ·Jing Liu, Jake S. O’Donnell, Juming Yan, Jason Madore, Stacey Allen, Mark J. Smyth, Michele W.L. Teng	2019	68
9	Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155 Annals of Oncology ·Sebastian Rojek, Jason Madore, Jake S. O’Donnell, Rebecca L. Johnston, Melissa Eastgate, Domenico Mallardo, Paolo A. Ascierto, Daniela Massi, Barbara Merelli, Mario Mandalà, James S. Wilmott, Tobias Bald, J. C. A. Stagg, Bertrand Routy, Georgina V. Long, Richard A. Scolyer, Nicola Waddell, William C. Dougall, Michele W.L. Teng, Mark J. Smyth	2019	1
10	Cancer immunoediting and resistance to T cell-based immunotherapy Nature Reviews Clinical Oncology ·Jake S. O’Donnell, Michele W.L. Teng, Mark J. Smyth Hit paper breakdown →	2018	1258
11	Batf3⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy OncoImmunology ·Jing Liu, Elisa A. Rozeman, Jake S. O’Donnell, Stacey Allen, Lorenzo F. Fanchi, Mark J. Smyth, Christian U. Blank, Michele W.L. Teng	2018	50
12	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer OncoImmunology ·Elizabeth Ahern, Heidi Harjunpää, Jake S. O’Donnell, Stacey Allen, William C. Dougall, Michele W.L. Teng, Mark J. Smyth	2018	69
13	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux Seminars in Cancer Biology ·Jake S. O’Donnell, Daniela Massi, Michele W.L. Teng, Mario Mandalà	2017	312
14	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease Cancer Discovery ·Jing Liu, Stephen J. Blake, Michelle C.R. Yong, Heidi Harjunpää, Shin Foong Ngiow, Kazuyoshi Takeda, Arabella Young, Jake S. O’Donnell, Stacey Allen, Mark J. Smyth, Michele W.L. Teng Hit paper breakdown →	2016	569
15	Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade? Genome Medicine ·Jake S. O’Donnell, Mark J. Smyth, Michele W.L. Teng	2016	54
16	The voltage gated Ca2+-channel Cav3.2 and therapeutic responses in breast cancer Cancer Cell International ·Johanna Scabell, Elke Kaemmerer, Michael J. G. Milevskiy, Kunsala T. D. S. Yapa, Jake S. O’Donnell, Melissa A. Brown, Fiona Simpson, Amelia A. Peters, Sarah J. Roberts‐Thomson, Gregory R. Monteith	2016	35
17	Resistance to PD1/PDL1 checkpoint inhibition Cancer Treatment Reviews ·Jake S. O’Donnell, Georgina V. Long, Richard A. Scolyer, Michele W.L. Teng, Mark J. Smyth Hit paper breakdown →	2016	429

About Jake S. O’Donnell

Jake S. O’Donnell is a scholar working on Immunology, Oncology, Agronomy and Crop Science, Infectious Diseases and Ecology, Evolution, Behavior and Systematics, having authored 17 papers that have together received 3.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (10 papers), CAR-T cell therapy research (6 papers), T-cell and Retrovirus Studies (3 papers), Animal Disease Management and Epidemiology (3 papers), Vector-Borne Animal Diseases (2 papers), Cancer Cells and Metastasis (2 papers) and Melanoma and MAPK Pathways (1 paper). The work is most often cited by research in Oncology (2.1k citations), Immunology (1.4k citations), Cancer Research (353 citations), Pulmonary and Respiratory Medicine (662 citations) and Molecular Biology (885 citations). Jake S. O’Donnell has collaborated with scholars based in Australia, Italy and Netherlands. Frequent co-authors include Michele W.L. Teng, Mark J. Smyth, Georgina V. Long, Richard A. Scolyer, Daniela Massi, Mario Mandalà, Stacey Allen, Heidi Harjunpää, Stephen J. Blake and Kazuyoshi Takeda. Their work appears in journals such as OncoImmunology, Seminars in Cancer Biology, Frontiers in Microbiology, Nature Reviews Clinical Oncology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact